Allogene Therapeutics Inc. (ALLO), a clinical-stage biotechnology company, is scheduled to present new data from its ongoing phase I TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) on November 8, 2024.
TRAVERSE is an ongoing phase I trial designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com